Key result
New classes of anticoagulants, including direct thrombin inhibitors and Factor Xa inhibitors, show promise for improved efficacy, safety, and convenience compared to warfarin in atrial fibrillation.
Direct thrombin inhibitors and Factor Xa inhibitors show promise as alternatives to warfarin for stroke and systemic embolism prevention in atrial fibrillation.
Anticoagulation is vital for stroke and systemic embolism prevention in patients with atrial fibrillation. Current therapy with the vitamin K inhibitor warfarin has many inherent limitations in clinical practice. With the potential of broadening anticoagulation therapy to a larger population, new classes of anticoagulants have recently emerged with the potential for improved efficacy, safety and convenience. Direct thrombin inhibitor and Factor Xa inhibitor classes are showing promise for both patients and clinicians.
No takes yet. Share an insight, caveat, or question.
Bhusri et al. (2011) conducted a review in Atrial fibrillation. New anticoagulants (Direct thrombin inhibitors and Factor Xa inhibitors) vs. Warfarin was evaluated. New classes of anticoagulants, including direct thrombin inhibitors and Factor Xa inhibitors, show promise for improved efficacy, safety, and convenience compared to warfarin in atrial fibrillation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: